

Tranexamic acid to reduce blood loss at unplanned caesarean delivery

Submission date 17/07/2024	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 29/07/2024	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 25/07/2024	Condition category Pregnancy and Childbirth	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Background and study aims

Caesarean deliveries (births by abdominal operation) are increasing worldwide. Excessive bleeding at caesarean delivery is common and can cause other complications including death. Bleeding is increased at unplanned caesarean deliveries compared to planned. Tranexamic acid was originally used for more than 50 years to treat heavy periods. Tranexamic acid stabilizes blood clots by slowing their breakdown reducing or stopping bleeding. It is effective and safe to use in many situations, such as treatment where major bleeding has occurred or prevention where major bleeding is predicted. Recent studies on tranexamic acid used to prevent major bleeding during caesarean section showed confounding results of benefit or no benefit but it appeared safe. Tranexamic acid given slowly after the baby has been delivered but still within the caesarean may not be effective. There remains a knowledge gap on how long before and also how quickly the tranexamic acid dose should be administered at a caesarean for it to be optimally beneficial. These points on timing and speed of administration are especially important in an unplanned (emergency) caesarean where many care measures need to be performed within a short space of time. The past studies on tranexamic acid are in planned caesarean or a mixture of planned and unplanned caesarean cases. There remains a need for further data to provide support that tranexamic acid given speedily before the operation starts (so is likely to be active in the blood before bleeding begins) reduces bleeding as a result of the surgery.

Who can participate?

Adult patients aged 18 years old and over who are in labour (defined as 2 or more contractions every 10 minutes the neck of the womb opened to at least 3 cm) and have a caesarean delivery decided (emergency or unplanned)

What does the study involve?

After obtaining written informed consent, participants will be randomly allocated to one of the trial interventions by a computer. Neither the patient nor your doctor can choose or is aware of which agent is given. A syringe containing 10 ml colourless solution (containing 1 g tranexamic acid or normal saline) will be given to the care provider for administration within the operating theatre. Standard patient care will be applied throughout the hospital stay from preoperative prophylactic measures to intraoperative and postoperative care for all participants. Within 3

days after the caesarean before hospital discharge, a 3 ml blood sample will be drawn (if one was not already performed for routine post-caesarean care) and sent to the hospital laboratory for a complete blood count. This result will be taken together with the blood count routinely taken for women admitted for birth to calculate blood loss at caesarean. Before discharge participants will be asked to rate their energy level using a 0 to 10 rating scale. In all other respects, routine care will be provided to all participants.

What are the possible benefits and risks of participating?

Participants should not expect any benefit as it is not fully established whether tranexamic acid will reduce, or have no effect on blood loss during an emergency caesarean section. However, it is anticipated that blood loss will be reduced but the reduction may or may not be sufficient to minimise further complications like the need for blood transfusion. The investigators plan to publish the findings of this study in a high-impact research journal to help guide care during caesarean section and; hopefully, to show that tranexamic acid can safely reduce blood loss at an unplanned caesarean delivery. A research publication output is an achievement that may enhance career prospects.

Participants should not expect major harm as tranexamic acid has a good and long safety record in a variety of clinical settings. Hypothetically though, tranexamic acid may increase the risk of complications related to blood clots in leg veins or the lungs though increased risk has been demonstrated after many years of use and extensive research on this type of risk. Significant allergic reactions to tranexamic acid are rare. The investigators do not have a monetary or other material stake involved whatever the outcome of this study.

Where is the study run from?

University Malaya Medical Centre (Malaysia)

When is the study starting and how long is it expected to run for?

September 2023 to January 2025

Who is funding the study?

Department of Obstetrics and Gynaecology, Faculty of Medicine, University Malaya, (Malaysia)

Who is the main contact?

Dr Shnkari Govindasamy, g.shnkari@ummc.edu.my

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr Shnkari Govindasamy

Contact details

Lembah Pantai

Wilayah Persekutuan Kuala Lumpur

Malaysia

59100

+601137066166

g.shnkari@ummc.edu.my

Additional identifiers

Study information

Scientific Title

Prophylactic tranexamic on blood loss at uplanned caesarean section delivery: a double-blind randomised trial

Study objectives

Tranexamic acid will reduce blood loss at unplanned caesarean delivery

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 26/06/2024, Medical Research Ethics Committee, University of Malaya Medical Centre (Lembah Pantai, Wilayah Persekutuan Kuala Lumpur, 59100, Malaysia; +60379492030; ummc-mrec@ummc.edu.my), ref: 2023922-12898

Primary study design

Interventional

Study design

Single-center interventional randomized double-blind controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Unplanned caesarean delivery

Interventions

1. The interventions are:

a) 1 g tranexamic acid (10 ml solution) to be given by slow intravenous injection over 30-60 seconds

OR

b) 10 ml of normal saline to be given by slow intravenous injection over 30-60 seconds

To be administered as soon as possible after entry to the operating theatre

After obtaining written informed consent, participants will be randomized to the one of the trial interventions by the opening of a numbered, sealed and opaque envelope (lowest numbered envelope remaining to the newest recruit). A syringe containing 10 ml colourless solution (containing 1 g tranexamic acid or normal saline) will be given to the care provider for administration within the operating theatre. Participants and care providers are masked to the agent allocated. Standard patient care will be applied throughout the hospital stay from preoperative prophylactic measures to intraoperative and postoperative care to all participants. Within 3 days of the caesarean before hospital discharge, a 3 ml blood sample will be drawn (if one was not already performed for the purpose of routine post- caesarean care) and sent to the hospital laboratory for a complete blood count. This result will be taken together with the blood

count routinely taken for women admitted for birth to calculate blood loss at caesarean. Prior to discharge participants will be asked to rate their energy level using a 0 to 10 rating scale. In all other respects, routine care will be provided to all participants.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Tranexamic acid

Primary outcome(s)

Calculated total blood loss measured using data collected from hospital laboratory records on preoperative (most recently within 8 days before surgery) and postoperative (closest to day 2 after delivery) haematocrit values

Key secondary outcome(s)

The following secondary outcome measures are assessed using the stated data at one time point:

1. Blood loss ≥ 1000 ml measured using recorded calculated total blood loss
2. Blood transfusion measured using data from hospital records
3. Transfusion of other blood products up to hospital discharge measured using data from hospital records
4. Uterotonic agent other than oxytocin up to hospital discharge measured using data from hospital records
5. Surgical or radiologic intervention up to hospital discharge measured using data from hospital records
6. Open-label use of tranexamic acid up to hospital discharge measured using data from hospital records
7. Acute kidney injury up to hospital discharge measured using data from hospital records
9. Postoperation duration of hospital stay measured using data from hospital records
9. Thromboembolic event, ischemic stroke, or myocardial infarction up to hospital discharge measured using data from hospital records
10. New-onset seizure up to hospital discharge measured using data from hospital records
11. Admission to ICU and indication up to hospital discharge measured using data from hospital records
12. Participant energy level measured using an 11- point 0-10 Numerical Rating Scale at hospital discharge
13. Participant side effects cumulative up to hospital discharge measured using data from the participants on:
 - 13.1. Nausea
 - 13.2. Vomiting
 - 13.3. Dizziness
14. Apgar score at 1 and 5 min measured using data from hospital records
15. Umbilical cord artery blood pH measured using data from hospital records
16. Neonatal intensive care admission and indication up to hospital discharge measured using data from hospital records
17. Neonatal thromboembolism up to hospital discharge measured using data from hospital records

Completion date

01/01/2025

Eligibility

Key inclusion criteria

1. Age ≥ 18 years old
2. At term (≥ 37 weeks)
3. Able to fully understand Malay or English
4. Live fetus
5. Emergency/unplanned CS in labour (contractions ≥ 2 in 10 min, cervix ≥ 3 cm)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Upper age limit

50 Years

Sex

Female

Key exclusion criteria

1. Clinical indication for tranexamic acid
2. Contraindication to tranexamic acid
3. Known hypersensitivity to tranexamic acid
4. Known placenta previa/placenta accreta spectrum
5. Contraindications to tranexamic acid
6. Suspected current thromboembolic events
7. Known thrombophilia, coagulopathy or severe renal disease
8. History of venous thromboembolism

Date of first enrolment

01/09/2024

Date of final enrolment

31/10/2024

Locations

Countries of recruitment

Malaysia

Study participating centre
University Malaya Medical Centre
Lembah Pantai
Kuala Lumpur
Malaysia
59100

Sponsor information

Organisation
University Malaya Medical Centre

ROR
<https://ror.org/00vkrxq08>

Funder(s)

Funder type
University/education

Funder Name
Universiti Malaya

Alternative Name(s)
University of Malaya, University Malaya, Malayan University, King Edward VII College of Medicine, Raffles College, University of Malaya in Singapore, , , , UM

Funding Body Type
Government organisation

Funding Body Subtype
Universities (academic only)

Location
Malaysia

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and /or analysed during the current study are/will be available upon request from Dr Shnkari Govindasamy, g.shnkari@ummc.edu.my

IPD sharing plan summary

Available on request